ReviewPharmaceutics2022
Combinatorial Therapeutic Approaches with Nanomaterial-Based Photodynamic Cancer Therapy.
Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 54 citations in OpenAlex.
- Photodynamic Therapy Combined with Anticancer Drug Therapy in the Treatment of Malignant Neoplasms.Cells · 2026Review
- Research Progress of Nanodelivery Platforms in the Diagnosis and Treatment of Esophageal Cancer.International journal of nanomedicine · 2026Review
- Folate-Modified Albumin-Functionalized Iron Oxide Nanoparticles for Theranostics: Engineering and In Vitro PDT Treatment of Breast Cancer Cell Lines.Pharmaceutics · 2025Article
- Large animal models for investigating the applications of photodynamic therapy.Zoological research · 2025Review
- Protein-based nanoparticles for antimicrobial and cancer therapy: implications for public health.RSC advances · 2025Review
- Development of Small Interfering RNA Loaded Cationic Lipid Nanoparticles for the Treatment of Liver Cancer with Elevated α-Fetoprotein Expression.ACS bio & med chem Au · 2025Article
- Nanomaterials for Theranostic Management of Oral Cancer: Advances in Imaging, Biosensing, Targeted Delivery, and Multimodal Synergistic Therapy.International journal of nanomedicine · 2025Review
- Conjugated Human Serum Albumin/Gold-Silica Nanoparticles as Multifunctional Carrier of a Chemotherapeutic Drug.International journal of molecular sciences · 2024Article
- Nanogel-Carbon Dot Conjugates: A Synergistic Approach for Enhanced Cancer Treatment through Combination Therapy.ACS medicinal chemistry letters · 2024Article
- Unlocking the Potential of Gold as Nanomedicine in Cancer Immunotherapy.Journal of nanotheranostics · 2024Article
- Towards overcoming obstacles of type II photodynamic therapy: Endogenous production of light, photosensitizer, and oxygen.Acta pharmaceutica Sinica. B · 2024Review
- The quest for nanoparticle-powered vaccines in cancer immunotherapy.Journal of nanobiotechnology · 2024Review
- Versatile Design of Organic Polymeric Nanoparticles for Photodynamic Therapy of Prostate Cancer.ACS materials Au · 2024Review
- Enhancing cancer therapy: advanced nanovehicle delivery systems for oridonin.Frontiers in pharmacology · 2024Review
- Synergized photothermal therapy and magnetic field induced hyperthermia via bismuthene for lung cancer combinatorial treatment.Materials today. Bio · 2023Article
- Photothermal Effect of Gold Nanoparticles as a Nanomedicine for Diagnosis and Therapeutics.Pharmaceutics · 2023Review
- Review
- Combinations of Photodynamic Therapy with Other Minimally Invasive Therapeutic Technologies against Cancer and Microbial Infections.International journal of molecular sciences · 2023Review
- Drug Delivery in Photodynamic Therapy.Pharmaceutics · 2023Article
- Autophagy Regulation Using Multimodal Chlorin e6-Loaded Polysilsesquioxane Nanoparticles to Improve Photodynamic Therapy.Pharmaceutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Photodynamic therapy (PDT), in which a light source is used in combination with a photosensitizer to induce local cell death, has shown great promise in therapeutically targeting primary tumors with negligible toxicity and minimal invasiveness. However, numerous studies have shown that noninvasive PDT alone is not sufficient to completely ablate tumors in deep tissues, due to its inherent shortcomings. Therefore, depending on the characteristics and type of tumor, PDT can be combined with surgery, radiotherapy, immunomodulators, chemotherapy, and/or targeted therapy, preferably in a patient-tailored manner. Nanoparticles are attractive delivery vehicles that can overcome the shortcomings of traditional photosensitizers, as well as enable the codelivery of multiple therapeutic drugs in a spatiotemporally controlled manner. Nanotechnology-based combination strategies have provided inspiration to improve the anticancer effects of PDT. Here, we briefly introduce the mechanism of PDT and summarize the photosensitizers that have been tested preclinically for various cancer types and clinically approved for cancer treatment. Moreover, we discuss the current challenges facing the combination of PDT and multiple cancer treatment options, and we highlight the opportunities of nanoparticle-based PDT in cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.